

*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.*

#### Premium Sponsors



#### Standard Sponsors



## UK Myeloma Society Autumn Day

### Integration of Immunotherapies in Myeloma Care and Amyloid Update

Thursday 6<sup>th</sup> November 2025

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

*Register to attend in person or watch a live stream*

**Joint Chairs: Dr Charlotte Pawlyn** (Institute of Cancer Research)

**Professor Karthik Ramasamy** (Churchill Hospital, Oxford)

09.00 *Registration, coffee & exhibition*

09.25 Welcome and introduction

09.30 UK practice/access updates

09.50 College of Myeloma UK - reflections on careers in myeloma

**Professor Karthik Ramasamy**  
Churchill Hospital, Oxford

**Dr Roger Owen**  
Leeds Teaching Hospitals

**Professor Mark Drayson**  
University of Birmingham

#### EHA Abstract Award Winners

10.10 Challenging the concept of functional high-risk myeloma through advanced transcriptional and genetic profiling

Age-associated macrophage polarization to an M2 phenotype drives myeloma proliferation in the aged bone marrow by loss of tumor-associated phagocytosis

**Dr Sina Beer**  
Institute of Cancer Research

**Dr Dominic Fowler-Shorten**  
University of East Anglia

10:25 *Coffee & exhibition*

#### IMS Abstract Award Winners

The perceptions of frailty and how frailty is assessed in patients living with myeloma – a qualitative exploration of patient perspectives

Monitoring and management of CMV and other viral reactivations with bispecific antibodies (BsAbs) for patients with relapsed and refractory multiple myeloma (RRMM)

Investigating the role of the BAFF-APRIL system in promoting progression of smouldering myeloma (SMM)

Anti-adhesion properties of KTX-1001, a selective NSD2/MMSET inhibitor, enhance carfilzomib sensitivity in multiple myeloma

**Jenna Tate**  
Leeds Teaching Hospitals

**Dr Alice Feast**  
University College London Hospitals

**Dr Amatta Mirandari**  
University College London

**Dr Devi Nandana**  
University of Oxford

#### Michael Morley Lecture

11.30 Opportunities and challenges with immunotherapy in myeloma

12.20 *Lunch, networking & exhibition*

13.20 *AGM*

**Dr Paola Neri**  
University of Calgary

## Parallel Sessions: Clinical and Scientific

### UKMRA Science Forum

*In person attendance only. See next page for more information.*

### PORTLAND ROOM

13.40  
15.10  
15.45  
16.30

Speakers  
Coffee break  
Networking and collaboration session  
Summary and close

*If you wish to attend this session, please ensure that you select the appropriate package when completing your registration. Places are limited.*

### Clinical Session 1: Optimising the Safe Delivery of Immunotherapies in the NHS – Practical Implementation Updates

13.40 Prevention and management of side effects with CAR-T/bispecifics

**Dr Hannah Hunter**  
*University Hospitals Plymouth*

13.55 Outpatient bispecific/CAR T delivery experience

**Dr Frances Seymour**  
*Leeds Teaching Hospitals*

14.10 DGH bispecific delivery experience

**Dr John Jones**  
*University of Sussex*

14.25 Safe delivery of ADCs

**Dr Kevin Boyd**  
*The Royal Marsden*

14.40 Panel discussion with case studies

14.55 *Coffee break*

### Clinical Session 2: AL Amyloidosis Update

15.25 Updates in overall AL amyloid management for 2025

**Dr Sriram Ravichandran**  
*National Amyloidosis Centre*

15.40 Focus on – cardiac amyloidosis

**Dr Charlotte Manisty**  
*Barts Health NHS Trust*

15.55 Focus on – renal amyloidosis and MGRS

**Dr Jenny Pinney**  
*University Hospitals Birmingham*

16.10 Interactive discussion: Structure and function of the new Amyloid network

**Professor Ashu Wechalekar**  
*National Amyloidosis Centre*

**Professor Guy Pratt**  
*University of Birmingham*

16.40 *Close*

### Registration:

Standard Fee (until 22 October)  
£75 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 23 October)  
£125 (£85 for Scientists, Nurses & Pharmacists)

**Registration now open at [www.collaborativeconferences.co.uk/ukmsociety](http://www.collaborativeconferences.co.uk/ukmsociety)**

*Online registration for this meeting is for healthcare professionals only  
Please indicate if you wish to attend in person or watch the live stream while completing the registration form*

**Enquiries: Please contact Alex - [alex@collaborativeconferences.co.uk](mailto:alex@collaborativeconferences.co.uk)**

*The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials*

### Premium Sponsors

 **Binding Site**  
CELL-CELL INTERACTION SOLUTIONS

 **MENARINI**  
group

 **Sternline**  
A Menarini Group Company

**Johnson & Johnson**  
**Innovative Medicine**

 **Pfizer**

 **GSK**

**sanofi**

### Standard Sponsors

 **Bristol Myers Squibb**

 **Adaptive**  
biotechnologies

 **Takeda**

**AMGEN**

 **GILEAD** |  **Kite**

*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.*



## UKMRA Science Forum at the UK Myeloma Society Autumn Day

Thursday 6<sup>th</sup> November 2025

Cavendish Conference Centre - PORTLAND ROOM

### Leading the Session:

**Dr Shelly Lawson** (*Sheffield*) and **Dr Sarah Gooding** (*Oxford*)

|       |                                                                                                                                                  |                                                                   |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 13.40 | Identifying tumour specific T cell clones in smouldering myeloma                                                                                 | <b>Annabel Laider</b><br><i>University College London</i>         |
| 13.55 | In vivo CRISPR activation screens for developing CAR T cells with superior persistence                                                           | <b>Jongwon Yoon</b><br><i>University College London</i>           |
| 14.10 | Origins of mitotic lethality in high-CIN multiple myeloma                                                                                        | <b>Alex Fower</b><br><i>University of Oxford</i>                  |
| 14.25 | Prevention, not cure: Investigating MGUS and the challenges of finding a needle in the peripheral blood haystack                                 | <b>Dr Hannah Mackay</b><br><i>University of Birmingham</i>        |
| 14.40 | How do exosomes contribute to treatment failure, with the aim of uncovering key molecular mechanisms driving drug resistance in multiple myeloma | <b>Chloe Wylie</b><br><i>Queen's University Belfast</i>           |
| 14.55 | The role of compass methyltransferase in multiple myeloma                                                                                        | <b>Dr Pierangela Sabbattini</b><br><i>Imperial College London</i> |
| 15.10 | <i>Coffee break</i>                                                                                                                              |                                                                   |
| 15.45 | Networking / collaboration session (speed networking)                                                                                            |                                                                   |
| 16.30 | Summary and close                                                                                                                                |                                                                   |

### Premium Sponsors



### Standard Sponsors



*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.*